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INTRODUCTION
HbF (α2γ2), the main haemoglobin component in the
foetus, is present at levels of 65 to 90% at birth and
usually drops to less than 2% by 6 to 12 months of
age(1). HbF levels may also be elevated as a result of
genetic abnormalities of  haemoglobin production or
because of  haemopoietic stress.
After birth, the HbF- gama-gene is switched down
and the HbA beta-gene is switched on so that adults
mainly produce HbA ( 2β2). After this developmental
switch, low levels of HbF are still produced, and this
is distributed heterogeneously with some red cells (F
cells) expressing more HbF than others (2). The level
of  HbF, and the associated proportion of  F cells, is a
highly heritable trait (3), and within a normal popula-
tion the distribution of HbF is much skewed. Most
healthy individuals produce <0.6% HbF distributed
among 1–7% F cells, but a small proportion (about
2%) produce up to 5% HbF and 25% F cells and such
individuals are said to have heterocellular hereditary
persistence of fetal Hb (hHPFH) (4). SCA patients with
high HbF levels not only have less severe clinical course,
but also have mild clinical complications because an
increase in haemoglobin F inhibits polymerization of
sickle haemoglobin.
The varying levels of foetal haemoglobin in erythro-
cytes account for a larger part of clinical heterogene-
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ABSTRACT
Aim: - Elevated HbF, among other biological and environmental
factors, is responsible for decrease in mortality in sickle cell anaemia
(SCA). This study determined the levels of  HbF in adult SCA pa-
tients in steady state compared with HbAA controls. HbF was dis-
cussed in line with the clinical course of the disease so as to empha-
size the relevance of hydroxyurea in the management of adult SCA
patients.
Materials and methods: - The HbF levels of  66 confirmed SCA pa-
tients and 31 HbAA controls were estimated using Betke method
and HbF percentage was calculated using formula: %HbF percent-
age = A413 filtrate x 100A413 standard x 20.
Result: - A statistical significant difference in the mean of the levels
of HbF in patients (5.16±4.04) compared to controls (1.04±0.44)
(p = 0.000) was observed. The mean levels of  HbF for males
(4.71±3.49) compared to that of females (4.99) were statistically simi-
lar (p =0.773). It was also observed that the mean HbF level appears
to be declining as age advances. SCA patients were classified to
three categories viz: HbF <2% (21.2% SCA patients); HbF of 2.1%
-10%, (68.2% SCA patients); and HbF of 10.1% -16%, (10.6% SCA
patients).
Conclusion: - Substantial proportion of our patients actually will
require treatment with hydroxylurea to stimulate HbF production
especially those with HbF percentage of <2 and some with HbF
percentage of 2.1 – 10%. HPFH may be considered rare since only
10. 6% had HbF at the range of 10.1-16%. This study showed that in
treating our SCA patients in Nigeria we need to adopt and encour-
age the use of HbF activating agents like hydroxyurea or any other
safe agent that will be found to stimulate HbF production in SCD
patients.
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ity observed in patients with sickle cell anaemia(5). It is
also a major prognostic factor for several clinical com-
plications. (6, 7, 8)
The strong relationship existing between percentage
HbF level and disease severity in SCA suggests that
baseline measurement of percentage HbF is paramount
in predicting important aspects of clinical course and
in advocating usage of hydroxyurea, which is in low
ebb in Nigeria, in order to achieve as much as 40%
reduction in mortality long observed in SCA by
Steinberge et al in 2003 (9)
MATERIALS AND METHODS
Subjects
Ninety seven subjects were enrolled. This included 66
SCA patients in steady state attending Medical Out
Patient clinic who were consecutively recruited into
the study after an informed consent. Also, 31 consent-
ing healthy, HbAA adults were enrolled into the study.
These were medical health workers or voluntary blood
donors.
Sample Collection
Five milliliters of venous blood was collected by clean
venepuncture from each patient via the ante-cubital
vein using a plastic syringe with minimum stasis, into
commercially prepared concentrations of sequestrene
ethylene di-amine tetra-acetic acid (EDTA) bottles.
Each sample was mixed gently and thoroughly to en-
sure anticoagulation and to prevent cell lysis. One mil-
liliter of this blood was used to prepare haemolysate
for HbF estimation and haemoglobin electrophoresis
using Cellulose acetate at pH 8.6 to confirm HbA and
HbS status.
Methodology
Measurement of HbF was done using the Betke
method (10). HbF percentage was calculated using the
formula: % HbF = A413 filtrate x100 A413 standard x
20
Statistical Analysis
Statistical analysis was performed using SPSS 15.0.
Results were expressed as mean ± SD. The difference
between mean was compared using the Student’s t
test.
RESULTS
Ninety seven subjects made up of 66 diagnosed SCA
(HbS) and 31 normal HbA controls were recruited.
In the 66 SCA patients, 28 were males while 38 were
females with a mean age of 27.9±10.4 (age range 15
to 60 years). The control subjects have a mean age of
30.6±8.1 years. There was no statistically significant
difference in age of the controls and the patients (p =
0.314).
The mean HbF level for the control was 1.04±0.44
(range 0.2- 1.7) while the mean for the SCA patients
was 5.16±4.04. The difference in the mean HbF when
compared was statistically significant (p = 0.000). In
the SCA patients; the mean for males of 4.71 was
slightly lower than the mean for females 4.99 although
not statistically significant. (p = 0.773).
While the mean HbF in the controls fall within normal
range of <1.5%; 45(68.2%) of the SCA patients has a
raised HbF of within the range of 2.1%-10% and
7(10.6%) had HbF >10%. (Table2). Table 1 also
showed the mean HbF level per particular age range,
A g e H b S S M e a n  H b F ( % )
< 2 0 1 1  ( 1 6 . 7 % ) 5 . 0 5 ± 3 . 8 9
2 0 - 3 0 3 7  ( 5 6 . 1 % ) 5 . 4 2 ± 4 . 2 2
3 0 - 4 0 1 0  ( 1 5 . 2 % ) 3 . 9 3 ± 2 . 8 3
> 4 0 8  ( 1 2 . 1 % ) 3 . 2 9 ± 3 . 8 2
T o ta l 6 6  ( 1 0 0 % ) 5 . 1 6  ±  4 .0 4
T a b l e  1 : M e a n  H b F  i n  d i f f e r e n t  a g e  G r o u p s
i n  S C A  p a t i e n t s .
H b F  L e v e l
A g e / y e a r s
< 2 % 2 . 1 % - 1 0 % > 1 0 % T o t a l
< 2 0 1 ( 1 . 5 % ) 9 ( 1 3 . 6 % ) 1 ( 1 . 5 % ) 1 4 (1 6 . 7 % )
2 1 - 3 0 3 ( 7 . 6 % ) 2 7 (4 0 . 9 % ) 5 ( 7 . 6 % ) 8 ( 5 6 . 1 % )
3 1 - 4 0 3 ( 4 . 5 % ) 7 ( 1 0 . 6 % ) 0 ( 0 % ) 7 ( 1 5 . 2 % )
> 4 0 5 ( 7 . 6 % ) 2 ( 3 . 0 % ) 1 ( 1 . 5 % ) 8 ( 1 2 . 5 % )
T o t a l 1 4 (2 1 . 2 % ) 4 5 (6 8 . 2 % ) 7  ( 1 0 . 6 % ) 6 6  ( 1 0 0 % )
T a b l e  2 :- S h o w s  s t r a t i f i c a t i o n  o f  L e v e ls  o f H b F  a c c o r d i n g  t o  d e g r e e  o f  e le v a t i o n  a n d a g e  g r o u p
i n  S C D  p a t i e n t s .
highlighting a steady decline in the mean HbF levels as
age advances.
DISCUSSION
Foetal haemoglobin, a heritable traits in adults account-
ing for substantial phenotypic diversity of sickle cell
disease; was estimated in both control subjects (HbAA
and known HbSS patients in steady state for com-
parison. The mean haemoglobin F (HbF) level ex-
pected in HbAA controls is supposed to be <1.5%(11)
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and the derived mean of 1.04 in this study was within
normal. Earlier studies obtained a mean foetal hae-
moglobin level of 6.4±4.0% (12) and 7.4±3.6% (13) but
the mean HbF of 5.16 in this study is slightly lower
than both earlier values. However, the mean HbF of
patients obtained in this study is in agreement with
previous studies (14). Although, the mean of HbF in
females of 4.99 was slightly higher than that of males
(4.71), there was no statistically significant difference
(p = 0.773). This finding may not agree with com-
parative survival curve analysis study which found that
male HbSS patients had a better overall prognosis than
females (15) .Another local study found a statistically
higher level of  HbF in males than females. (13)
Sickle cell anaemia (SCA) was the first human mono-
genic disorder to be characterized at the molecular
level (16) and up to this moment there is yet to be a
cure. It results from the substitution of glutamic acid
by valine at position 6 of the beta-chain of haemo-
globin. The clinical manifestations of SCD arise from
the tendency of sickle haemoglobin to polymerize at
reduced oxygen tensions and deform red cells into
the characteristic rigid sickle cell shape. Such inflexible
red cells cannot pass through the microcirculation ef-
ficiently, and this results in anaemia (due to destruction
of  the red cells) and intermittent vaso-occlusion caus-
ing tissue damage and pain (17). This watershed arising
from sickled haemoglobin is inhibited in patients with
elevated HbF level.
Although all patients with  SCA have exactly the same
molecular defect, there is considerable clinical varia-
tion, ranging from death in early childhood (18), to a
normal life span with few complications(4) due to the
influence of genetic modifiers of SCA like co-exist-
ence of á –thalassemia (19). Therefore, patients with
increased levels of HbF often tend to have a relatively
mild clinical course (20) because HbF reduces the ten-
dency of HbS to polymerize within the red cell. This
highlights the need to determine HbF along with HbA2
in assisting to differentiate  HbSS,  HbS-beta-thalas-
semia and HbS-HPFH and hence determination of
HbA2 and HbF should graduate from research activ-
ity to routine tool in order to project the management
of SCA to a level where the clinical course among
others could be easily predicted at diagnosis.
Genetic studies have established that increased HbF
level  may result from rare deletions within the beta-
globin gene cluster or from point mutations in the
promoters of the fetal gamma-globin genes (heredi-
tary persistence of fetal haemoglobin, HPFH), how-
ever,  additional loci are known to increase HbF levels
in adult life, which has been identified using combina-
tion of genome-wide analysis within a large kindred(21)
and within twin pairs(22), leading to identification of
two quantitative trait loci (QTL) with major influences
on fetal hemoglobin levels in adults. Lettre et al (23) had
shown that a significant proportion of the variation in
HbF levels and the frequency of painful crises in pa-
tients with SCA, are accounted for by five common
single-nucleotide polymorphisms (SNPs) at these loci.
A pharmacologic agent, Hydroxyurea, ( produced and
in use since 1994), and  its effectiveness was affirmed
when a large multicenter, randomized, double blind
placebo study in America of 299 subjects showed that
the drug significantly reduced not only the frequency
and severity of painful crises, but also the incidence of
acute chest syndrome, and blood transfusion require-
ments (24). Its precise mechanism of action is unknown
but it causes an increase in fetal haemoglobin concen-
trations in most subjects by physically interfering with
the polymerization process of  deoxyhaemoglobin S.
Although hydroxyurea is not a cure for sickle cell dis-
ease but it should, at present, be offered to our se-
verely affected SCA patients since the risk of severely
symptomatic disease and early death is correlated with
the fetal haemoglobin concentration (25). The drug will
be beneficial to 21% of SCA patients in this study
whose %HbF levels fell below 2% and some of the
68.2% with %HbF ranging between 2.1%- 10.0%.
It is highly imperative to always estimate not only the
levels of  HbF, but also of  HbA2 so as to be able to
clearly define the clinical course of every sickle cell
disease patient. Resource poor countries should be
assisted to equip their haemoglobinopathy laborato-
ries to be able to have and use freely, equipments like
Isoeletric focusing, High Performance Liquid Chro-
matographic (HPLC) studies and radial immunodif-
fusion, that will distinctly separate and quantify all hae-
moglobin variants.
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